The final, formatted version of the article will be published soon.
REVIEW article
Front. Neurosci.
Sec. Neuroenergetics and Brain Health
Volume 19 - 2025 |
doi: 10.3389/fnins.2025.1514253
This article is part of the Research Topic Insights in Neuroenergetics and Brain Health: 2024 View all articles
Disulfidptosis: A new target for central nervous system disease therapy
Provisionally accepted- 1 College of Medicine，Hunan University of Traditional Chinese Medicine, Changsha, Anhui Province, China
- 2 Institute of Clinical Pharmacology of Chinese Meteria Medica, Changsha, China
- 3 Key Laboratory of Hunan Province for integrated Tranditional Chinese and Western Medicine on Prevention and Treatment of Cardio-cerebral Diseases, Changsha, China
Disulfidptosis is a pathologic process that occurs under conditions of NADPH deficiency and excess disulfide bonds in cells that express high levels of SLC7A11. This process is caused by glucose deprivation-induced disulfide stress and was first described by cancer researchers. Oxidative stress is a hypothesized mechanism underlying diseases of the central nervous system (CNS), and disulfide stress is a specific type of oxidative stress. Proteins linked to disulfidptosis and metabolic pathways involved in disulfidptosis are significantly associated with diseases of the CNS (neurodegenerative disease, neurogliomas and ischemic stroke). However, the specific mechanism responsible for this correlation remains unknown. This review provides a comprehensive overview of the current knowledge regarding the origin elements, genetic factors, and signaling proteins involved in the pathogenesis of disulfidptosis. It demonstrates that the disruption of thiometabolism and disulfide stress play critical roles in CNS diseases, which are associated with the potential role of disulfidptosis.We also summarize disulfidptosis-related drugs and highlight potential therapeutic strategies for treating CNS diseases. Additionally, this paper suggests a testable hypothesis that might be a promising target for treating CNS diseases.
Keywords: disulfidptosis, thiometabolism, Thiol/disulfide, Central Nervous System Diseases, therapy
Received: 20 Oct 2024; Accepted: 27 Jan 2025.
Copyright: © 2025 Chang, Liu, Xiao, Tan, Deng, Mei and Liao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Danhong Liu, Institute of Clinical Pharmacology of Chinese Meteria Medica, Changsha, China
Yuqi Xiao, College of Medicine，Hunan University of Traditional Chinese Medicine, Changsha, Anhui Province, China
Boyao Tan, College of Medicine，Hunan University of Traditional Chinese Medicine, Changsha, Anhui Province, China
Jun Deng, Institute of Clinical Pharmacology of Chinese Meteria Medica, Changsha, China
Jun Liao, Key Laboratory of Hunan Province for integrated Tranditional Chinese and Western Medicine on Prevention and Treatment of Cardio-cerebral Diseases, Changsha, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.